文献速递甲状腺疾病

细胞学不确定甲状腺结节的分子变异及其恶性风险

Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.
PubMed 文献 · Thyroid · 2019-09-27

该系统综述纳入2009至2018年61项研究、超过4600个细胞学不确定甲状腺结节(ITN),汇总术前细针穿刺(FNA)基因变异及其恶性阳性预测值(PPV)。26%的结节携带至少一种变异或融合;BRAFV600E的PPV为98%(95%CI 96-99%),其余四种报告≥10次的变异PPV为38%-55%,同一结节多变异累积PPV为77%。

要点

  • BRAFV600E预测恶性风险最高,PPV达98%。
  • PAX8/PPARG、HRASQ61R、BRAFK601E、NRASQ61R的PPV介于38%-55%。
  • 同一结节检出多种变异时累积恶性风险升高至77%。

核心结论

  • 基因组变异预测恶性的概率取决于具体变异或融合类型。
  • 仅五种变异报告次数≥10次,BRAFV600E的PPV为98%,其余四种为38%-55%。

研究设计与样本

  • 系统综述,检索2009至2018年发表的术前FNA标本遗传数据研究,纳入后续手术切除的细胞学不确定甲状腺结节。
  • 共61项研究符合标准,纳入超过4600个ITN。

主要发现

  • 26%的结节携带至少一种变异或融合。
  • BRAFV600E的PPV为98%(95%CI 96-99%)。
  • PAX8/PPARG的PPV为55%(95%CI 34-78%)。
  • HRASQ61R的PPV为45%(95%CI 22-72%)。
  • BRAFK601E的PPV为42%(95%CI 19-68%)、NRASQ61R的PPV为38%(95%CI 23-55%);排除BRAFV600E后其他明确变异/融合的汇总PPV为47%。

关键数值与推荐

  • 报告≥10次的变异PPV:BRAFV600E 98%(95%CI 96-99%)、PAX8/PPARG 55%(95%CI 34-78%)、HRASQ61R 45%(95%CI 22-72%)、BRAFK601E 42%(95%CI 19-68%)、NRASQ61R 38%(95%CI 23-55%)。
  • 同一结节多种变异的累积PPV为77%,约占ITN的1%。

临床怎么用

  • 解读ITN分子结果时应按具体变异/融合分别评估恶性概率,而非统一视为高风险。
  • BRAFV600E阳性对恶性预测价值高,其他变异需结合临床与细胞学综合判断。

局限性

  • 半数结节未报告具体基因、变异和/或完整融合配对信息,影响PPV计算。
  • 大多数变异和融合对样本量小,单个PPV点估计的置信度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Gene panels are routinely used to assess predisposition to hereditary cancers by simultaneously testing multiple susceptibility genes and/or variants. More recently, genetic panels have been implemented as part of solid tumor malignancy testing assessing somatic alterations. One example is targeted variant panels for thyroid nodules that are not conclusively malignant or benign upon fine-needle aspiration (FNA). We systematically reviewed published studies from 2009 to 2018 that contained genetic data from preoperative FNA specimens on cytologically indeterminate thyroid nodules (ITNs) that subsequently underwent surgical resection. Pooled prevalence estimates per gene and variant, along with their respective positive predictive values (PPVs) for malignancy, were calculated. Summary: Our systematic search identified 540 studies that were supplemented by 18 studies from bibliographies or personal files. Sixty-one studies met all inclusion criteria and included >4600 ITNs. Overall, 26% of nodules contained at least 1 variant or fusion. However, half of them did not include details on the specific gene, variant, and/or complete fusion pair reported for inclusion toward PPV calculations. The PPVs of genomic alterations reported at least 10 times were limited to BRAFV600E (98%, 95% confidence interval [CI 96-99%]), PAX8/PPARG (55% [CI 34-78%]), HRASQ61R (45% [CI 22-72%]), BRAFK601E (42% [CI 19-68%]), and NRASQ61R (38% [CI 23-55%]). Excluding BRAFV600E, the pooled PPV for all other specified variants and fusions was 47%. Multiple variants within the same nodule were identified in ∼1% of ITN and carried a cumulative PPV of 77%. Conclusions: The chance that a genomic alteration predicts malignancy depends on the individual variant or fusion detected. Only five alterations were reported at least 10 times; BRAFV600E had a PPV of 98%, while the remaining four had individual PPVs ranging from 38% to 55%. The small sample size of most variants and fusion pairs found among ITNs, however, limits confidence in their individual PPV point estimates. Better specific reporting of genomic alterations with cytological category, histological subtype, and cancer staging would facilitate better understanding of cancer prediction, and the independent contribution of the genomic profile to prognosis.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Goldner WS, Angell TE, McAdoo SL, et al. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules. Thyroid. 2019. PMID: 31469053. doi:10.1089/thy.2019.0278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。